On July 30, 2025, the National Medical Products Administration formally approved the New Drug Application for Ranicabtagene Autoleucel Injection (HICARA®) submitted by Shanghai Hengrun Dasheng Biotechnology Co., Ltd. . HICARA® is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more prior systemic therapies.